Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Play Is for xB3
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Dec 27, 2022 9:13pm
135 Views
Post# 35193017

RE:RE:The Play Is for xB3

RE:RE:The Play Is for xB3If this is true and there is the appearance of malfeasance and a breach of fiduciary duties by the CEO and others in management, then they need to be held accountable. Too bad Dr Rath seems to be too chicken to explain herself and provide shareholders with any rationale to a seemingly horrific deal. The problem though is who will bring an action against her/the company and lead the investigation? Who will pay for it? Does any shareholder, who has spent years owning this stock only to see their $$ evaporate, want to engage in such a battle? Maybe that is what the company is counting on. Shareholders will whine and cry but no one will or can to anything about it. I doubt anyone wants to lose any more money on this company than they already have
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities